Trending Market News

Brent crude oil spot prices surged to $141.36 per barrel, the highest level since the 2008 financial crisis, driven by severe physical supply constraints. The spike reflects urgent demand for oil deliveries within 10-30 days amid major disruptions caused by a U.S.-Iran conflict that has impacted the Strait of Hormuz. The spot price jumped $32.33 above June futures contracts, indicating futures markets are not fully reflecting the severity of the supply crisis.

• Spot prices for immediate delivery (10-30 days) reached $141.36, while June futures traded $32.33 lower, suggesting futures markets are 'masking the true tightness' of supply conditions
• Diesel prices in Europe have soared to nearly $200 per barrel, further demonstrating the acute shortage of refined petroleum products
• Industry experts warn that closure of the Strait of Hormuz has created 'very real, physical manifestations' working through global supply chains that are not yet fully priced into futures markets

The National Labor Relations Board has ordered Amazon to negotiate with the Amazon Labor Union, which represents approximately 5,000 workers at a Staten Island warehouse. The NLRB ruled that Amazon engaged in unfair labor practices by refusing to bargain with or recognize the union, which formed in 2022 and has since aligned with the International Brotherhood of Teamsters. Amazon disputes the ruling and plans to appeal.

• The union, formed independently in 2022, has been seeking negotiations over pay, working conditions, and other workplace matters before aligning with the Teamsters
• The NLRB found Amazon 'engaged in unfair labor practices' by refusing to bargain with the union or recognize its legitimacy
• Amazon claims NLRB representatives 'improperly influenced' the election and states it is confident an unbiased court will overturn the original certification

President Trump secured agreements with 17 major pharmaceutical companies to align U.S. prescription drug prices with those in other developed nations in exchange for three-year tariff exemptions on drug imports. The companies committed to 'most-favoured-nation' pricing, agreed to sell drugs directly to consumers through a new government platform called TrumpRx.gov, and pledged billions in U.S. investments. Discounts range from 50% to 85% on various medications including diabetes, weight-loss, and specialty drugs.

• Novo Nordisk reduced Ozempic and Wegovy prices from $1,000-$1,350 per month to $350 through TrumpRx, while offering insulin products at $35 per month
• Bristol Myers Squibb agreed to provide blood-thinner Eliquis to Medicaid for free and donate over seven tons of active pharmaceutical ingredient
• Companies including Pfizer, AstraZeneca, and Amgen committed to discounts of 60-85% off list prices through direct-to-patient platforms and TrumpRx.gov

President Trump secured agreements with 16 major pharmaceutical companies to align U.S. prescription drug prices with those in other developed nations through 'most-favoured-nation' pricing. In exchange, these companies receive three-year exemptions from tariffs on drug imports and will sell drugs directly to consumers through a new government platform called TrumpRx.gov.

• Major drugmakers including Pfizer, Novo Nordisk, and Eli Lilly agreed to discounts ranging from 50% to 85% on select medications through TrumpRx.gov
• Novo Nordisk's Ozempic and Wegovy prices will drop from $1,000-$1,350 per month to $350, while insulin products will be available at $35 per month
• Companies committed billions in U.S. investments and agreed to launch future drugs at prices comparable to other developed countries; only Regeneron has yet to sign among the 17 companies contacted

Regeneron Pharmaceuticals expects to be excluded from new U.S. tariffs targeting drugmakers that have not agreed to lower drug prices. The company anticipates announcing a deal with the Trump administration soon to reduce prescription drug prices for Medicaid and cash-paying patients. Regeneron is the only one of 17 large drugmakers that received a letter from President Trump in July that has not yet signed such an agreement.

• The Trump administration plans to announce new tariffs as soon as Thursday against drugmakers without price reduction agreements
• Regeneron is the sole holdout among 17 large pharmaceutical companies that received letters from President Trump in July requesting price commitments
• Other drugmakers have already committed to 'most-favoured-nation' pricing, selling drugs through a new government platform, and pledged billions in U.S. investments

Coinbase Global has received conditional approval from the Office of the Comptroller of the Currency for a national trust company charter, which would allow it to operate as a federally regulated crypto custodian. Full approval could enable the U.S.'s largest cryptocurrency exchange to offer new products like tokenized securities and stablecoins, making it more attractive to institutional investors.

• Federal charter would let Coinbase expand its custody business under a federal framework and conduct new business activities previously unavailable
• The approval comes amid a more crypto-friendly regulatory environment since President Trump's re-election, with regulators easing prior restrictions
• Crypto.com also received similar national trust bank charter approval from the OCC earlier this year

The UK and US have finalized a pharmaceutical trade agreement that grants British-made medicines tariff-free access to the US market for at least three years. The deal, part of a broader US-UK trade accord signed last year, makes Britain the only country with zero-tariff pharmaceutical access to the United States. The agreement was announced by the British government on April 2.

• British pharmaceutical exports will enter the US market with zero tariffs for a minimum of three years under the finalized partnership
• Britain becomes the only country globally with tariff-free access for medicines to the US market
• The pharmaceutical deal is part of a wider US-UK trade accord that was signed in the previous year

A U.S. judge granted preliminary approval to Bank of America's $72.5 million settlement with women who accused the bank of facilitating Jeffrey Epstein's sex trafficking. The second-largest U.S. bank denied the claims but agreed to settle to provide closure for accusers, with 60-75 victims expected to file claims. A final approval hearing is scheduled for August 27.

• Bank of America faced allegations it ignored suspicious transactions related to Epstein's crimes, prioritizing profit over victim protection
• Plaintiffs' lawyers may seek up to 30% of the settlement ($21.8 million) in legal fees, with victims primarily based in the U.S. and Eastern Europe
• The same legal team previously secured settlements of $290 million from JPMorgan Chase and $75 million from Deutsche Bank in 2023 for Epstein accusers

Ford Motor reported a nearly 9% decline in first-quarter U.S. sales, reflecting broader automotive industry challenges stemming from affordability concerns. The drop highlights how high vehicle prices continue to impact consumer purchasing behavior in the American market.

• Ford's Q1 U.S. sales fell approximately 9% compared to the previous year
• The decline is attributed to ongoing affordability issues affecting the broader auto industry
• The sales drop signals continued pressure on automakers as consumers struggle with high vehicle costs

Coca-Cola launched its first multi-restaurant advertising campaign featuring 13 chains including Domino's, Wendy's, and Wingstop to boost beverage sales as the restaurant industry faces declining traffic and sluggish growth. The campaign highlights high-margin drinks as crucial for restaurant profitability amid consumer spending cutbacks, with U.S. restaurant traffic falling 2% in February 2026.

• 13 restaurant partners are featured in commercials showing customers ordering meals 'And a Coke,' with chains not paying to participate as it is described as a 'perk of being a partner with Coca-Cola'
• 38% of consumers reported spending less at restaurants in Q1 2026, prompting Coke to act as a 'business partner' by providing marketing funds and strategic support to chains
• Coke's domestic unit case volume fell 1% in 2025 despite 4% revenue growth, with foodservice representing roughly half of away-from-home sales and serving as a bellwether for overall consumer sentiment

KKR raised $23 billion for its North America Fund XIV (NAX4), the firm's largest-ever fund focused on the region. The successful raise underscores strong investor appetite for private equity as high-profile companies like OpenAI increasingly choose to remain private longer and avoid public market volatility. KKR's private equity assets under management have grown to approximately $229 billion, roughly doubling since 2020.

• NAX4 will target opportunistic private equity investments across North America, with the three predecessor funds delivering 23% gross returns over the past decade
• KKR's private equity AUM reached $229 billion, approximately double the 2020 level, reflecting rapid growth in the firm's private markets business
• The fund attracted diverse investors including pension plans, sovereign wealth funds, insurers, endowments, and private wealth platforms, both new and existing

Activist shareholder Follow This and investors managing $1 trillion are urging BP shareholders to reject a company-backed resolution that would eliminate climate-reporting requirements adopted in 2015 and 2019. BP needs at least 75% shareholder support to rescind the commitments, which require detailed climate strategy reporting and link executive pay to climate performance. The investors are also threatening legal action after BP refused to include a separate resolution calling for disclosure of BP's strategy under scenarios of declining oil and gas demand.

• Follow This filed a resolution with about 0.27% combined BP stake calling for long-term strategy disclosure under declining demand scenarios, but BP refused to include it on the AGM agenda
• BP argues existing climate-reporting requirements have been superseded by mandatory disclosure frameworks, while investor group warns current BP direction may expose the company to legal risks
• Follow This has filed a similar climate resolution ahead of Shell's May 19 AGM, continuing its pattern of using shareholder resolutions to pressure oil majors on climate strategy

OPEC+ is likely to consider increasing oil output at a meeting on Sunday, despite the ongoing closure of the Strait of Hormuz due to a U.S.-Israeli war with Iran. The move would position key producers to add barrels once the strait—which handles over 20% of global oil transit—reopens, as crude prices have surged to nearly $120 per barrel, a four-year high.

• The Strait of Hormuz closure has caused the largest oil supply disruption on record, forcing top OPEC producers Saudi Arabia, Iraq, Kuwait, and UAE to cut output significantly.
• OPEC+ agreed to a modest 206,000 bpd increase for April at its March 1 meeting; any new increase would be largely symbolic ('on paper') to signal readiness once shipping resumes.
• Saudi Arabia has rerouted exports through Yanbu on the Red Sea to near capacity (4.6 million bpd), while UAE exports from Fujairah rose to 1.61 million bpd in March, accounting for nearly half its pre-war total exports.

AstraZeneca announced that a combination treatment using its cancer drug Imfinzi, along with Imjudo and lenvatinib, significantly improved progression-free survival in late-stage liver cancer patients when combined with standard chemoembolisation procedures. The interim results also showed improvements in overall survival compared to the standard TACE procedure alone for unresectable hepatocellular carcinoma.

• The Imfinzi combination showed statistically significant and clinically meaningful improvement in progression-free survival versus TACE (transarterial chemoembolisation) alone for treating unresectable hepatocellular carcinoma
• Analysts at JP Morgan and Citi forecast peak annual sales of approximately $11.3 billion for the Imfinzi + Imjudo combination, exceeding current market expectations of $10.6 billion
• AstraZeneca executive Susan Galbraith indicated that starting the treatment regimen earlier alongside TACE and lenvatinib could further improve patient outcomes

Immunovant announced on Thursday that its therapy for treating a type of eye disease failed to meet the main goals in a late-stage clinical trial. The failure represents a significant setback for the company's drug development program.

• The experimental treatment failed to achieve its primary endpoints in the late-stage study
• This marks a critical development failure at the final testing phase before potential regulatory approval

China's commerce ministry stated it supports lawful international business deals, responding to scrutiny over Meta's $2 billion acquisition of Chinese AI startup Manus. Chinese regulators have barred two Manus co-founders from leaving the country while reviewing whether the deal violated investment rules.

• Meta's acquisition of Chinese AI startup Manus is valued at $2 billion and is under regulatory review
• China has prevented two Manus co-founders from leaving the country during the investigation into potential investment rule violations
• Commerce ministry spokesperson He Yadong emphasized China's support for transnational operations and technology deals that comply with legal requirements

European stocks fell sharply after U.S. President Trump announced plans to hit Iran 'extremely hard' over the next two to three weeks of expected conflict. The pan-European Stoxx 600 dropped 1.25%, with mining and tech sectors leading declines of 2.8% and 3% respectively, while oil prices surged over 6% to $107.98 per barrel.

• Major European indexes declined significantly: Germany's DAX fell 1.50%, France's CAC 40 dropped 1.27%, and Spain's IBEX lost 1.56%
• Global oil prices have skyrocketed more than 60% in March following U.S. and Israeli strikes on Iran on Feb. 28, marking the biggest monthly gain since records began in the 1980s
• The Trump administration is reportedly preparing new tariffs on countries that haven't agreed to guarantee low drug prices in the U.S., adding to market uncertainty

Amazon is in talks to acquire Globalstar, a satellite telecommunications company, in a deal valued at $9 billion according to the Financial Times. The potential acquisition would expand Amazon's presence in the satellite communications sector. Details of the negotiations remain limited as discussions are ongoing.

• The acquisition would be valued at approximately $9 billion, representing a significant investment in satellite infrastructure
• Globalstar is a satellite telecommunications group that operates a constellation of low-Earth orbit satellites
• The deal aligns with Amazon's existing Project Kuiper satellite internet initiative and could strengthen its space-based connectivity capabilities

The U.S. International Trade Commission launched a Section 337 patent violation investigation into streaming devices and components imported by Roku and Hisense. Las Vegas-based InnoTV Labs filed the complaint, requesting exclusion and cease and desist orders against the imports. The investigation targets display devices, streaming players, and components from Roku Inc., Purple Tag Media Technology Shanghai, and Hisense Visual Technology Co.

• InnoTV Labs alleges patent violations by Roku (San Jose-based), Purple Tag Media Technology Shanghai, and Hisense Visual Technology Co. (Qingdao, China) along with related companies
• The petitioner has requested the USITC issue a limited exclusion order and cease and desist orders to block the allegedly infringing imports
• The investigation covers certain display devices, streaming players, and components imported by the named companies

U.S. cosmetics giant Estee Lauder and Spanish beauty firm Puig are in advanced talks for a merger that would be structured primarily as a stock-based transaction, according to Bloomberg News. The deal could be formally announced within weeks, marking a significant consolidation in the global beauty industry.

• The transaction would consist mostly of stock rather than cash, suggesting a merger-of-equals structure between the two beauty companies
• A formal announcement could come within weeks, indicating negotiations are in late stages
• The combination would unite a major U.S. cosmetics player with a Spanish beauty firm, creating a larger international beauty conglomerate